

# Zachary Dovey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3464116/publications.pdf>

Version: 2024-02-01

21  
papers

301  
citations

1163117

8  
h-index

940533

16  
g-index

21  
all docs

21  
docs citations

21  
times ranked

642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. <i>Communications Biology</i> , 2020, 3, 374.	4.4	112
2	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, e17-e54.	1.8	39
3	Immunotherapy in prostate cancer: current state and future perspectives. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722095140.	2.0	24
4	Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2020, 204, 82-90.	0.4	24
5	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 457-472.	1.0	21
6	Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings. <i>European Urology Oncology</i> , 2022, 5, 187-194.	5.4	20
7	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	1.4	13
8	Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. <i>European Urology Open Science</i> , 2020, 20, 1-11.	0.4	10
9	Why do African-American men face higher risks for lethal prostate cancer?. <i>Current Opinion in Urology</i> , 2022, 32, 96-101.	1.8	8
10	Repurposing of $\beta$ -Adrenoceptor Antagonists: Impact in Renal Cancer. <i>Cancers</i> , 2020, 12, 2442.	3.7	7
11	Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, . . .	1.6	6
12	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. <i>Cancers</i> , 2022, 14, 2734.	3.7	5
13	Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. <i>Cancer Reports</i> , 2022, 5, e1492.	1.4	3
14	COVID-19 in patients with and without cancer: Examining differences in patient characteristics and outcomes. , 2021, 2, 25-32.		2
15	Current strategies to improve erectile function in patients undergoing radical prostatectomy-intraoperative scenario. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 79-79.	1.6	2
16	Prostate cancer biomarkers: a practical review based on different clinical scenarios. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 297-308.	6.1	2
17	Access and socioeconomic status play an important role in outcomes for African American patients with prostate cancer. <i>Cancer</i> , 2020, 126, 4257-4258.	4.1	1
18	Impact of diverticular disease on prostate cancer risk among hypertensive men. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 700-706.	3.9	1

#	ARTICLE	IF	CITATIONS
19	Current strategies to improve erectile function in patients undergoing radical prostatectomy - preoperative scenario. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	1
20	Current strategies to improve erectile function in patients undergoing radical prostatectomy - postoperative scenario. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
21	Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology. Prostate, 2022, , .	2.3	0